Navigation Links
Mylan Announces Change in Board Leadership
Date:5/7/2009

- Co-founder Mike Puskar retires as Chairman of the Board -

- Robert J. Coury elected Chairman of the Board -

PITTSBURGH May 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced a change in leadership to its Board of Directors. Mylan co-founder and chairman Milan ("Mike") Puskar announced that he is stepping down as Chairman of the Board effective immediately and that he will retire as a director effective Oct. 1. The board subsequently elected Mylan's Vice Chairman and CEO Robert J. Coury to succeed Puskar as Chairman of the Board.

Upon his election Coury stated: "On behalf of the Board of Directors and all of Mylan's employees and shareholders, I would like to personally thank Mike Puskar for his many accomplishments; his impact on the industry; and for his service and leadership. Mike will truly, truly be missed."

Coury continued, "I am also extremely honored to add the chairman role to my current responsibilities as Chief Executive Officer of Mylan. At this time, I would also like to announce that Rod Piatt, who has served as a member of our Board of Directors for the past five years, has been appointed Vice Chairman of the Board of Directors."

Puskar co-founded Mylan as a privately held drug distributor with Don Panoz in 1961. He has been a director of the company for the past 33 years, serving as its chairman since 1993. Puskar also was the company's president from 1976 to 2000 and CEO from 2000 until 2002. His tenure has been marked by a steady and strong leadership position among generic pharmaceuticals companies in the U.S. As one of the industry's pioneers, Puskar built a legacy on quality manufacturing, unparalleled customer service and policy leadership.

Puskar commented: "The time has come for me to step down as chairman, and I am more than confident that under Robert's passionate and strategic direction, Mylan will continue to provide leadership for an industry that is continually evolving. Robert has taken what we started almost 50 years ago and turned it into a global powerhouse with a vast reach that is unique among our peers. I would like to congratulate him on his remarkable accomplishments to date, and I wish him all the best as he executes on his vision for the next 50 years."

Coury has been Mylan's Vice Chairman and CEO since 2002 and had previously served as a consultant to the company from 1995 to 2002. Under his leadership and strategic direction, the company transformed from the third largest generics company in the U.S. to the third largest generics and specialty pharmaceutical company in the world with the 2007 game-changing acquisitions of a majority interest in Matrix Laboratories and the global generics business of Merck KGaA. Prior to joining Mylan, Coury was the principal of Coury Consulting L.P., a corporate strategy advisory firm he formed in 1989 in Pittsburgh.

Piatt was elected to Mylan's board in 2004. He is a current member of the board's audit, finance, compensation and governance, and nominating committees. Piatt is the president and owner of Horizon Properties, a real estate development company he founded in 1996 as well as CEO and Director of Lincoln Manufacturing Inc., a steel and coal manufacturing company.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: